Abstract
Epigenetic abnormalities play important roles in the pathogenesis of Hodgkin lymphoma (HL). Highly expressed class I histone acetyltransferase (HDAC) and hyper-methylation of the promoter region of tumor suppressor genes have been demonstrated in Hodgkin lymphoma. In this paper, we investigated the synergistic effects of combination treatment of chidamide, a selective HDAC inhibitor, and decitabine, a demethylation agent, for HL cell lines and explored a new strategy for treating HL. The apoptosis rates, cell cycle, mitochondrial transmembrane potentials, epigenetic changes and gene expression of HL cell lines treated with chidamide as a single agent and in combination with decitabine were tested. We found that chidamide inhibited the proliferation of HL cells through increased apoptosis. Interestingly, after combined with decitabine, the inhibition rate and apoptotic death in HL cells were significantly increased. Further studies demonstrated that when combined with decitabine the expression of acetylated histone H3 and H3K9 induced by chidamide in HL cells increased, and also the expression of tumor suppressor genes PU.1 and KLF4, which exert inhibition through apoptosis pathway. Therefore, we could come to a conclusion that ...Continue Reading
References
Jan 19, 2000·Nature·B D Strahl, C D Allis
May 22, 2004·Cell Death and Differentiation·N KatoY Minami
Jul 31, 2004·Blood·Alexey UshmorovThomas Wirth
Aug 19, 2007·Leukemia & Lymphoma·Elizabeth R PlimackJean-Pierre Issa
Jun 11, 2008·Blood·Daniela BuglioAnas Younes
Mar 27, 2009·Leukemia·L YánezA Iriondo
Sep 25, 2009·British Journal of Haematology·Annunziata GloghiniAnas Younes
Apr 27, 2010·Expert Opinion on Therapeutic Targets·Heiner AdamsAlexandar Tzankov
Jun 4, 2010·Blood·Hanfeng GuanAlexey Ushmorov
Aug 6, 2010·Leukemia·R ShimizuY Furukawa
Aug 17, 2010·The American Journal of Pathology·Paul G MurrayQian Tao
Oct 1, 2010·British Journal of Haematology·Daniela BuglioAnas Younes
Oct 6, 2010·BMC Cancer·Sonja EberthHilmar Quentmeier
Mar 12, 2011·Haematologica·Volkhard SeitzMichael Hummel
Jul 21, 2011·Blood·Matko KalacOwen A O'Connor
Aug 23, 2011·Diagnostic Pathology·Qun-Pei YangWei-Ping Liu
Nov 15, 2011·Cancer Chemotherapy and Pharmacology·Zhi-Qiang NingXian-Ping Lu
Dec 14, 2011·The New England Journal of Medicine·Ralph M MeyerUNKNOWN Eastern Cooperative Oncology Group
Jan 25, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bastian von TresckowAndreas Engert
Feb 22, 2012·The Biochemical Journal·Ke GongWenhua Li
Mar 6, 2012·The Oncologist·Radhakrishnan Ramchandren
Aug 23, 2012·American Journal of Clinical Pathology·Jian SunJie Chen
Oct 12, 2012·Journal of Translational Medicine·Zhaohui WangQian Tao
Dec 6, 2012·Blood·Hiromichi YukiYutaka Okuno
Jan 24, 2013·The Journal of Pathology·Hanfeng GuanAlexey Ushmorov
Apr 2, 2013·Biochemical and Biophysical Research Communications·Zhixin QiaoQun Yu
May 25, 2013·Medical Oncology·Anna CzyzMieczysław Komarnicki
Nov 28, 2013·PloS One·Jan M KleinElke Pogge von Strandmann
Jan 8, 2014·Oncotarget·Vivek SubbiahDavid Hong
Jul 30, 2014·British Journal of Haematology·Christopher B BentonGuillermo Garcia-Manero
Aug 1, 2015·Proteomics·Simone Sidoli, Benjamin A Garcia
Citations
Nov 2, 2018·Human Gene Therapy·Yingxi XuJianxiang Wang
Sep 29, 2020·Frontiers in Oncology·Fang ZhuLiling Zhang
Jul 11, 2019·Oncology Letters·Xiang-Gui YuanXiao-Ying Zhao
Sep 1, 2021·BMC Cancer·Reid P BissonnetteMireille Gillings
Oct 3, 2021·Cell Death & Disease·Kai XueLan Wang